DrugPatentWatch Database Preview
Rucaparib camsylate - Generic Drug Details
What are the generic sources for rucaparib camsylate and what is the scope of patent protection?
Rucaparib camsylate
is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Rucaparib camsylate has two hundred and sixty-five patent family members in fifty-three countries.
One supplier is listed for this compound.
Summary for rucaparib camsylate
| International Patents: | 265 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 13 |
| Clinical Trials: | 5 |
| DailyMed Link: | rucaparib camsylate at DailyMed |
Recent Clinical Trials for rucaparib camsylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Clovis Oncology, Inc. | Phase 2 |
| ImmunoGen, Inc. | Phase 1 |
| Ohio State University Comprehensive Cancer Center | Phase 1 |
Pharmacology for rucaparib camsylate
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Synonyms for rucaparib camsylate
| [4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)phenyl]-N-methylmethanaminium [(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl]methanesulfonate |
| 1327258-57-0 |
| 1859053-21-6 |
| 41AX9SJ8KO |
| 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid |
| 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonicacid |
| 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1) |
| 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate |
| AC-30110 |
| AKOS032962880 |
| BCP18101 |
| Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1) |
| C0-338 |
| CHEBI:134692 |
| CHEMBL3833368 |
| CO-338 |
| CS-6939 |
| D10982 |
| EX-A3053 |
| HMS3750O21 |
| HY-102003 |
| PF-1367338-BW |
| Q27258428 |
| Rubraca (TN) |
| Rucaparib (Camsylate) |
| rucaparib camphorsulfonate |
| Rucaparib Camphosulfonate |
| Rucaparib camsylate (USAN) |
| Rucaparib camsylate, >=98% (HPLC) |
| SB16540 |
| SCHEMBL17512178 |
| UNII-41AX9SJ8KO |
US Patents and Regulatory Information for rucaparib camsylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for rucaparib camsylate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200600679 | Start Trial |
| Bulgaria | 65210 | Start Trial |
| Tunisia | SN05212 | Start Trial |
| Australia | 2004294790 | Start Trial |
| Spain | 2371469 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for rucaparib camsylate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2534153 | LUC00093 | Luxembourg | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529 |
| 1633724 | PA2015016,C1633724 | Lithuania | Start Trial | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| 2534153 | 122018000131 | Germany | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 20180524 |
| 2534153 | CA 2018 00041 | Denmark | Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLATE; REG. NO/DATE: EU/1/17/1250/001-003 20180529 |
| 1633724 | PA2015016 | Lithuania | Start Trial | PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
